Sunshine Biopharma Stock Scheduled to Reverse Split on Wednesday, April 17th (NASDAQ:SBFM)

Sunshine Biopharma, Inc. (NASDAQ:SBFM)’s stock is scheduled to reverse split on Wednesday, April 17th. The 1-100 reverse split was announced on Wednesday, April 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, April 17th.

Sunshine Biopharma Stock Performance

Sunshine Biopharma stock opened at $0.08 on Monday. Sunshine Biopharma has a 52 week low of $0.04 and a 52 week high of $1.40. The firm has a market cap of $7.97 million, a P/E ratio of -0.42 and a beta of 1.17. The business’s fifty day moving average is $0.09 and its two-hundred day moving average is $0.21.

Hedge Funds Weigh In On Sunshine Biopharma

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC increased its stake in shares of Sunshine Biopharma by 118.7% in the 4th quarter. Armistice Capital LLC now owns 2,130,000 shares of the company’s stock valued at $578,000 after buying an additional 1,156,000 shares during the period. Citadel Advisors LLC bought a new position in Sunshine Biopharma in the fourth quarter valued at about $50,000. Two Sigma Investments LP acquired a new stake in Sunshine Biopharma in the third quarter worth about $29,000. Virtu Financial LLC raised its holdings in Sunshine Biopharma by 242.8% during the 2nd quarter. Virtu Financial LLC now owns 47,861 shares of the company’s stock worth $52,000 after purchasing an additional 33,898 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Sunshine Biopharma during the 2nd quarter worth about $40,000. 41.98% of the stock is owned by institutional investors.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.